ClinicalTrials.gg
CompletedNCT00308737Updated Oct 16, 2014Results posted

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

A Phase 3 interventional study of Technosphere® Insulin Inhalation Powder and Usual Care in Diabetes, Type 1 and Diabetes, Type 2, sponsored by Mannkind Corporation. Completed at 176 sites in 8 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,053
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
Largest of 35
2,053 · median 74
Started
2005
with 3 others
Phase 3
17 of 35
none open now
Registered
3rd of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one has the largest enrollment, is one of 4 that started in 2005, is one of 17 in phase 3, and was the 3rd registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Pulmonary Safety in Diabetics with T/I

03

Conditions studied

  • Diabetes, Type 1
  • Diabetes, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For All Subjects:

    • Nonsmoking
    • \<42 kg/m2
    • greater than or equal to 70% of predicted , DLco and TLC greater than or equal to 80% of predicted at screening,
    • No abnormalities in screening pulmonary radiology
  • For Subjects with diabetes mellitus:

    • Type 1 or type 2 diabetes for at least 2 years
    • greater than or equal to 6.6 % and less than or equal to 12.0 %
  • For Subjects without abnormalities in glucose control:

    • No history of diabetes
    • Normal results from a formal glucose tolerance test

Exclusion criteria

Exclusion Criteria:

  • History of , asthma, or other significant pulmonary disease
  • Significant renal, hepatic, or cardiac disease
  • Women who are pregnant, lactating, or planning on becoming pregnant
  • Subjects who have participated in studies of other drugs within the previous 3 months
  • Evidence of severe complications of diabetes
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,053 participants (actual)

Study arms

  • Experimental
    TI Inhalation Powder

    Technosphere® Insulin Inhalation Powder

    Drug: Technosphere® Insulin Inhalation Powder

  • Other
    Usual care

    Usual care

    Drug: Usual Care

  • No intervention
    Non-diabetes

    Subjects without abnormalities in glucose control (Note: Hypoglycemia and HbA1c were not reported for this group)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care

    Change from Baseline to End of Study in FEV1 by MMRM

    Time frame: Baseline to Month 24

  2. FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care

    FEV1 decrease of ≥ 15% from Baseline value at last measurement

    Time frame: Baseline to Month 24

Secondary outcomes

  1. Change From Baseline to Last Measurement in FEV1 for TI vs Usual Care

    Change from Baseline to last measurement(Month 24) in FEV1

    Time frame: Baseline to Month 24

  2. Change From Baseline to Month 24 in Forced Vital Capacity (FVC) by MMRM

    Change from Baseline to Month 24 in FVC by MMRM

    Time frame: Baseline to Month 24

  3. Change From Baseline to Month 24 in Total Lung Capacity (TLC) by MMRM

    Change from baseline to Month 24 in TLC by MMRM

    Time frame: Baseline to Month 24

  4. Change From Baseline to Month 24 in Hemoglobin Corrected DLco by MMRM

    Change from baseline to Month 24 in hemoglobin-corrected DLco by MMRM

    Time frame: Baseline to Month 24

  5. Forced Vital Capacity (FVC) Decrease of ≥ 15% From Baseline Value at Last Measurement

    FVC Decrease of ≥15% from Baseline Value at Last Measurement

    Time frame: Baseline to Month 24

  6. Total Lung Capacity (TLC) Decrease of ≥ 15% From Baseline Value at Last Measurement

    TLC Decrease of ≥ 15% from Baseline Value at Last Measurement

    Time frame: Baseline to Month 24

  7. Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of ≥ 15% From Baseline Value at Last Measurement

    Hemoglobin-corrected DLco decrease of ≥ 15% from baseline value at last measurement

    Time frame: Baseline to Month 24

  8. Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of >3 ml/Min/mmHg From Baseline Value at Last Measurement

    Hemoglobin-corrected DLco decrease of \>3 ml/min/mmHg from baseline value at last measurement

    Time frame: Baseline to Month 24

  9. Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Last Measurement for TI vs Usual Care

    Change from baseline in HbA1c at last measurement

    Time frame: Baseline to Month 24

  10. Change in Weight From Baseline at Month 24

    Change from baseline in weight at Month 24

    Time frame: Baseline to Month 24

07

Results

Posted Oct 16, 2014

Participant flow

First subject enrolled July 25, 2005 Multi-national trial conducted in Canada, Czech Republic, Poland, Russia, Spain, Ukraine, UK, and US

Participant flow — Overall Study
MilestoneTechnosphere® InsulinUsual CareNon-diabetes
Started938951164
Completed475662127
Not completed46328937
Withdrew: Adverse event10490
Withdrew: Death430
Withdrew: Lost to follow-up56805
Withdrew: Physician decision1521
Withdrew: Protocol violation3495
Withdrew: Withdrawal by subject21816618
Withdrew: Various32208

Outcome measures

PrimaryChange From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care

Change from Baseline to End of Study in FEV1 by MMRM

Time frame:
Baseline to Month 24
Reported as:
Mean · liters
Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care
litersTechnosphere® InsulinUsual Care
Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care-0.16 ± 0.208-0.12 ± 0.211
Statistical analysis
  • Technosphere® Insulin vs Usual Care · Mixed Models Analysis · Mean difference (final values): 0.037 · 95% CI 0.014 to 0.060Repeated measures
SecondaryChange From Baseline to Last Measurement in FEV1 for TI vs Usual Care

Change from Baseline to last measurement(Month 24) in FEV1

Time frame:
Baseline to Month 24
Reported as:
Least squares mean · liters
Change From Baseline to Last Measurement in FEV1 for TI vs Usual Care
litersTechnosphere® InsulinUsual Care
Change From Baseline to Last Measurement in FEV1 for TI vs Usual Care-0.128 (-0.144 to -0.113)-0.092 (-0.107 to -0.077)
Statistical analysis
  • Technosphere® Insulin vs Usual Care · ANCOVA · Mean difference (final values): 0.037 · 95% CI 0.016 to 0.057
SecondaryChange From Baseline to Month 24 in Forced Vital Capacity (FVC) by MMRM

Change from Baseline to Month 24 in FVC by MMRM

Time frame:
Baseline to Month 24
Reported as:
Mean · liters
Change From Baseline to Month 24 in Forced Vital Capacity (FVC) by MMRM
litersTechnosphere® InsulinUsual CareNon-diabetes
Change From Baseline to Month 24 in Forced Vital Capacity (FVC) by MMRM-0.14 ± 0.242-0.11 ± 0.262-0.09 ± 0.210
Statistical analysis
  • Technosphere® Insulin vs Usual Care · Mixed Models Analysis · Mean difference (net): 0.034 · 95% CI 0.008 to 0.061Repeated measures
SecondaryChange From Baseline to Month 24 in Total Lung Capacity (TLC) by MMRM

Change from baseline to Month 24 in TLC by MMRM

Time frame:
Baseline to Month 24
Reported as:
Mean · liters
Change From Baseline to Month 24 in Total Lung Capacity (TLC) by MMRM
litersTechnosphere® InsulinUsual CareNon-diabetes
Change From Baseline to Month 24 in Total Lung Capacity (TLC) by MMRM-0.05 ± 0.321-0.07 ± 0.322-0.02 ± 0.297
Statistical analysis
  • Technosphere® Insulin vs Usual Care · Mixed Models Analysis · Mean difference (net): -0.005 · 95% CI -0.042 to 0.031Repeated measures
SecondaryChange From Baseline to Month 24 in Hemoglobin Corrected DLco by MMRM

Change from baseline to Month 24 in hemoglobin-corrected DLco by MMRM

Time frame:
Baseline to Month 24
Reported as:
Mean · mL/min/mmHg
Change From Baseline to Month 24 in Hemoglobin Corrected DLco by MMRM
mL/min/mmHgTechnosphere® InsulinUsual CareNon-diabetes
Change From Baseline to Month 24 in Hemoglobin Corrected DLco by MMRM-1.60 ± 2.830-1.36 ± 2.862-1.33 ± 3.203
Statistical analysis
  • Technosphere® Insulin vs Usual Care · Mixed Models Analysis · Mean difference (net): 0.269 · 95% CI -0.037 to 0.574Repeated measures
SecondaryForced Vital Capacity (FVC) Decrease of ≥ 15% From Baseline Value at Last Measurement

FVC Decrease of ≥15% from Baseline Value at Last Measurement

Time frame:
Baseline to Month 24
Reported as:
Number · participants
Forced Vital Capacity (FVC) Decrease of ≥ 15% From Baseline Value at Last Measurement
participantsTechnosphere® InsulinUsual CareNon-diabetes
Forced Vital Capacity (FVC) Decrease of ≥ 15% From Baseline Value at Last Measurement23172
Statistical analysis
  • Technosphere® Insulin vs Usual Care · Regression, Logistic · Odds ratio (or): 0.6475 · 95% CI 0.3432 to 1.2219
SecondaryTotal Lung Capacity (TLC) Decrease of ≥ 15% From Baseline Value at Last Measurement

TLC Decrease of ≥ 15% from Baseline Value at Last Measurement

Time frame:
Baseline to Month 24
Reported as:
Number · Participants
Total Lung Capacity (TLC) Decrease of ≥ 15% From Baseline Value at Last Measurement
ParticipantsTechnosphere® InsulinUsual CareNon-diabetes
Total Lung Capacity (TLC) Decrease of ≥ 15% From Baseline Value at Last Measurement761
Statistical analysis
  • Technosphere® Insulin vs Usual Care · Regression, Logistic · Odds ratio (or): 0.7504 · 95% CI 0.2510 to 2.2431
SecondaryHemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of ≥ 15% From Baseline Value at Last Measurement

Hemoglobin-corrected DLco decrease of ≥ 15% from baseline value at last measurement

Time frame:
Baseline to Month 24
Reported as:
Number · Participants
Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of ≥ 15% From Baseline Value at Last Measurement
ParticipantsTechnosphere® InsulinUsual CareNon-diabetes
Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of ≥ 15% From Baseline Value at Last Measurement10510820
Statistical analysis
  • Technosphere® Insulin vs Usual Care · Regression, Logistic · Odds ratio (or): 0.8953 · 95% CI 0.6703 to 1.1958
SecondaryHemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of >3 ml/Min/mmHg From Baseline Value at Last Measurement

Hemoglobin-corrected DLco decrease of \>3 ml/min/mmHg from baseline value at last measurement

Time frame:
Baseline to Month 24
Reported as:
Number · Participants
Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of >3 ml/Min/mmHg From Baseline Value at Last Measurement
ParticipantsTechnosphere® InsulinUsual CareNon-diabetes
Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of >3 ml/Min/mmHg From Baseline Value at Last Measurement18118140
Statistical analysis
  • Technosphere® Insulin vs Usual Care · Regression, Logistic · Odds ratio, log: 0.8509 · 95% CI 0.6722 to 1.0770
SecondaryChange From Baseline in Glycated Hemoglobin A1c (HbA1c) at Last Measurement for TI vs Usual Care

Change from baseline in HbA1c at last measurement

Time frame:
Baseline to Month 24
Reported as:
Mean · percentage
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Last Measurement for TI vs Usual Care
percentageTechnosphere® InsulinUsual Care
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Last Measurement for TI vs Usual Care-0.42 ± 1.410-0.49 ± 1.37
SecondaryChange in Weight From Baseline at Month 24

Change from baseline in weight at Month 24

Time frame:
Baseline to Month 24
Reported as:
Mean · kilograms
Change in Weight From Baseline at Month 24
kilogramsTechnosphere® InsulinUsual CareNon-diabetes
Change in Weight From Baseline at Month 241.0 ± 6.6531.64 ± 5.0661.19 ± 4.457
Statistical analysis
  • Technosphere® Insulin vs Usual Care · t-test, 2 sided · p = 0.112
PrimaryFEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care

FEV1 decrease of ≥ 15% from Baseline value at last measurement

Time frame:
Baseline to Month 24
Reported as:
Number · Participants
FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care
ParticipantsTechnosphere® InsulinUsual Care
FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care4227
Statistical analysis
  • Technosphere® Insulin vs Usual Care · Regression, Logistic · Odds ratio (or): -2.4767 · 95% CI -4.5578 to -0.3956

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Technosphere® Insulin—92/923 (10%)559/923 (60.6%)
Usual Care—91/949 (9.6%)472/949 (49.7%)
Non-diabetes—5/163 (3.1%)47/163 (28.8%)
Most frequent serious events
Showing 10 of 167
Most frequent serious events
EventTechnosphere® InsulinUsual CareNon-diabetes
HypoglycaemiaMetabolism and nutrition disorders9/92310/9490/163
Diabetes mellitus inadequate controlMetabolism and nutrition disorders1/9236/9490/163
AppendicitisInfections and infestations1/9231/9491/163
CellulitisInfections and infestations0/9231/9491/163
Chronic tonsillitisInfections and infestations0/9230/9491/163
TenosynovitisMusculoskeletal and connective tissue disorders0/9230/9491/163
Benign ovarian tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/9230/9491/163
Cerebrovascular accidentNervous system disorders1/9234/9491/163
Coronary artery diseaseCardiac disorders5/9233/9490/163
Diabetic ketoacidosisMetabolism and nutrition disorders5/9234/9490/163
Most frequent other events
Most frequent other events
EventTechnosphere® InsulinUsual CareNon-diabetes
HypoglycaemiaMetabolism and nutrition disorders365/923370/9490/163
CoughRespiratory, thoracic and mediastinal disorders257/92342/9495/163
Upper respiratory tract infectionInfections and infestations119/923143/94935/163
NasopharyngitisInfections and infestations67/92369/94914/163

Baseline characteristics

Safety population, excluding subjects who were not dosed with study medication (17 diabetics randomized but not dosed, 1 non-diabetic elected not to participate)

Age, Continuous
Age, Continuous(years)Technosphere® InsulinUsual CareNon-diabetesTotal
Mean50.8 ± 11.5550.4 ± 11.6238.2 ± 12.5949.6 ± 12.15
Sex: Female, Male
Sex: Female, Male(Participants)Technosphere® InsulinUsual CareNon-diabetesTotal
Female36637192829
Male557578711206
Body mass index
Body mass index(kilograms per meter squared)Technosphere® InsulinUsual CareNon-diabetesTotal
Mean29.87 ± 5.36629.76 ± 5.03525.27 ± 4.49429.5 ± 5.29
HbA1c
HbA1c(percentage)Technosphere® InsulinUsual CareNon-diabetesTotal
Mean8.7 ± 1.398.7 ± 1.380 ± 08.4 ± 1.61
Weight
Weight(kilograms)Technosphere® InsulinUsual CareNon-diabetesTotal
Mean87.69 ± 18.62887.53 ± 17.63874.35 ± 16.20486.6 ± 18.33
08

Study locations

176 sites
  • Southwest Health Ltd Research Division
    Phoenix, Arizona 85016, United States
  • Lovelace Scientific Resources
    Phoenix, Arizona 85018, United States
  • Northwest Medical Center
    Phoenix, Arizona 85029, United States
  • Arizona Center for Clinical Research
    Phoenix, Arizona 85032, United States
  • Premiere Pharmaceutical Research LLC
    Tempe, Arizona 85282, United States
  • Canyon Clinical Research
    Tucson, Arizona 85712, United States
  • Arizona Research Associates
    Tuscon, Arizona 85712, United States
  • Private Practice
    Burlingame, California 94010, United States
  • Saint Agnes Medical Center
    Fresno, California 93720, United States
  • Valley Research
    Fresno, California 93720, United States
  • (Private Practice)
    Garden Grove, California 92840, United States
  • Diabetes/Lipid Management Center
    Huntington Beach, California 92648, United States
  • Interlink Research Institute
    Los Alamitos, California 90720, United States
  • Diabetes Care Center
    Salinas, California 93901, United States
  • San Diego Sports Medicine and Family Health Center
    San Diego, California 92120, United States
  • Dorothy L & James E Frank Diabetes Research Institute
    San Mateo, California 94401, United States
  • Sansum Medical Research Institute
    Santa Barbara, California 93105, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Kaiser Permanente
    Denver, Colorado 80205, United States
  • Denver VA Medical Center
    Denver, Colorado 80220, United States
  • Alliance Medical Group of Greater Waterbury
    Middlebury, Connecticut 06762, United States
  • New Britain General Hosptal c?o Betsy Keller
    New Britain, Connecticut 06050, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Perimeter Institute for Clinical Research (PICR)
    Atlanta, Georgia 30338, United States
  • Executive Health and Research Associates Inc
    Atlanta, Georgia 30342, United States
  • Rockdale Medical Research Associates
    Conyers, Georgia 30094, United States
  • Private Practice
    Decatur, Georgia 30035-4000, United States
  • Atlanta Pharmaceutical Research Center
    Dunwoody, Georgia 30338, United States
  • North Atlanta Endocrinology & Diabetes PC
    Lawrenceville, Georgia 30045, United States
  • Southeastern Endocrine & Diabetes
    Roswell, Georgia 30076, United States
  • Fox Valley Clinical Research Center LLC
    Aurora, Illinois 60504, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Deerbrook Medical Associates
    Vernon Hills, Illinois 60061, United States
  • Medical Research of Louisiana
    Metairie, Louisiana 70001, United States
  • Ochsner Clinic and Foundation
    New Orleans, Louisiana 70121, United States
  • Health Trends Research LLC
    Baltimore, Maryland 21208-6391, United States
  • Franklin Square Hospital
    Baltimore, Maryland 21237, United States
  • MODEL Clinical Research
    Towson, Maryland 21204, United States
  • East Coast Clinical Research Inc
    Haverhill, Massachusetts 01830, United States
  • Clinical Research
    Waltham, Massachusetts 02453, United States
  • Michigan Institute of Medicine
    Livonia, Michigan 48152, United States
  • PPS Clinical Research / Southwest Medical Center
    Chesterfield, Missouri 63017, United States
  • Healthcare Research
    Florissant, Missouri 63031, United States
  • MedEx Healthcare Research Inc
    St Louis, Missouri 63117, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Mercy Health Research
    St. Louis, Missouri 63141, United States
  • Billings Clinic Research Division
    Billings, Montana 59101, United States
  • Your Doctors Care
    Hillsborough, New Jersey 08844, United States
  • Hopewell Valley Family Medicine PA
    Trenton, New Jersey 08618, United States
  • Umdnj-Som
    Voorhees, New Jersey 08084, United States
  • New Mexico Clinical Research & Osteoporosis Center
    Albuquerque, New Mexico 87106, United States
  • Lovelace Scientific Resources (Albuquerque)
    Albuquerque, New Mexico 87108, United States
  • Southwest Endocrinology Associates
    Albuquerque, New Mexico 87109, United States
  • Physicians Associates of Park Place
    Brooklyn, New York 11216, United States
  • Diabetes Care & Information Center of New York
    Flushing, New York 11365, United States
  • Eastside Comprehensive Medical Center
    New York, New York 10021, United States
  • M.E.R.I.
    New York, New York 10023, United States
  • Physicians Clinical Research Service (PCRS) (SMO)
    White Plains, New York 10604, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Endocrine Research - Physician's East PA
    Greenville, North Carolina 27834, United States
  • Rapid Medical Research Inc
    Cleveland, Ohio 44122, United States
  • Your Diabetes Endocrine Nutrition Group
    Mentor, Ohio 44060, United States
  • New Hope Research of Oregon
    Portland, Oregon 97219, United States
  • Buckingham Family Medicine
    Doyleston, Pennsylvania 18912, United States
  • Bucks County Clinical Research
    Morrisville, Pennsylvania 19067, United States
  • Upstate Pharmaceutical Research
    Greenville, South Carolina 29615, United States
  • Texas Familicare Clinical Research
    Colleyville, Texas 76034, United States
  • Dallas Diabetes & Endocrine Center
    Dallas, Texas 75230, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Houston Medical Research Associates
    Houston, Texas 77030, United States
  • North Texas Medical Research
    Plano, Texas 75093, United States
  • Diabetes & Glandular Disease Research Assoc PA
    San Antonio, Texas 78229, United States
  • Scott & White Hospital and Clinic
    Temple, Texas 76508, United States
  • McLennan County Medical Education and Research Foundation
    Waco, Texas 76707, United States
  • Magna Center for Family Medicine
    Magna, Utah 84044, United States
  • Davis Family Practice
    Salt Lake City, Utah 84041, United States
  • Radiant Research Salt Lake City
    Salt Lake City, Utah 84107, United States
  • Southeastern PA Med Inst LLC (SMO)
    Salt Lake City, Utah 84107, United States
  • Granger Medical Clinic
    West Valley City, Utah 84120, United States
  • Hampton Roads Center for Clinical Research Inc
    Norfolk, Virginia 23502, United States
  • Rainier Clinical Research Center Inc
    Renton, Washington 98055, United States
  • Clinical Research Department Wenatchee Valley Medical Center
    Wenatchee, Washington 98801, United States
  • Finchlea Medical Group
    Brampton, Ontario L6T 3J1, Canada
  • Courtice Health Centre
    Courtice, Ontario, Ontario L1E 3C3, Canada
  • Parkwood Hospital
    London, Ontario N6C 5J1, Canada
  • Quest Clinical Trials
    Markham, Ontario L6B 1A1, Canada
  • Sarnia Institute of Clinical Research
    Sarnia, Ontario N7T 4X3, Canada
  • The London Road Diagnostic Clinic and Medical Centre
    Sarnia, Ontario N7T 4X3, Canada
  • Lifestyle Metabolism Center
    Thornhill, Ontario L4J 8L7, Canada
  • Albany Medical Center
    Toronto, Ontario M4K 1N5, Canada
  • Lifestyle Metabolism Center (600-118 Eglinton Ave W)
    Toronto, Ontario M4R 2G4, Canada
  • Manna Research
    Toronto, Ontario M9W 4L6, Canada
  • Diabetologicka ambulance
    Litomerice, CZE 41201, Czech Republic
  • Surgery of Diabetology
    Melnik, CZE 276 01, Czech Republic
  • Internal Clinic
    Ostrava - Poruba, CZE 708 52, Czech Republic
  • Diabetologicka a interni ambulance
    Ostrava 1, CZE 70200, Czech Republic
  • Diabetologicka a interni ambulance
    Ostrava-Kuncice, CZE 70702, Czech Republic
  • Surgery of Diabetology Petrovice
    Prague 15, CZE 109 00, Czech Republic
  • FN Motol Interni Klinika
    Praha 6, CZE 150 06, Czech Republic
  • Klinika Endocrinologii Diabetologii I
    Bialystock, POL 15-276, Poland

Showing the first 100 of 176 sites across 8 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Sep 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 6 years 1 month after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2006
First posted
Mar 30, 2006
Start
Jun 2005
Primary completionActual
Sep 2008
CompletionActual
Oct 2008
Results delay requested
Jun 9, 2009
Results first posted
Oct 16, 2014
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00308737
Responsible party
Sponsor
First posted
Mar 30, 2006
Start date
Jun 2005
Primary completion
Sep 2008
Completion
Oct 2008
Results posted
Oct 16, 2014
Last update
Oct 16, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion